MedTrace Logo

Methods of T Cell Depletion Trial (MoTD)

NCT04888741 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2026-05-05

No results posted yet for this study

Summary

A multi-centre phase II trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin vs. Calcineurin inhibitor or Sirolimus-based post-transplant cyclophosphamide.

Conditions

Interventions

DRUG

Thymoglobulin

GVHD prophylaxis

DRUG

Cyclophosphamide

Post transplant cyclophosphamide strategy for GVHD prophylaxis

DRUG

Cyclosporine

immunosuppressant

DRUG

Sirolimus

immunosuppressant

DRUG

Mycophenolate Mofetil

immunosuppressant

Sponsors & Collaborators

  • The Jon Moulton Charity Trust

    collaborator UNKNOWN

  • IMPACT (funded by NHS Blood & Transplant, Anthony Nolan and Leukaemia UK)

    collaborator UNKNOWN

  • University of Birmingham

    lead OTHER

Principal Investigators

  • Ronjon Professor Chakraverty · Oxford Cancer & Haematology Centre, The Churchill Hospital, Old Road - Headington, Oxford, OX3 7LE Email: [email protected]

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-22
Primary Completion
2027-08-23
Completion
2027-08-23

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04888741 on ClinicalTrials.gov